,
by Nadia Jaber
A type of nivolumab that may be injected below the pores and skin (subcutaneous) has gained approval from the Meals and Drug Administration (FDA). The approval permits the injectable model for use for a lot of the identical affected person teams as the unique formulation, which is given as an infusion by a vein (intravenous or IV).
Consultants say the injectable model of nivolumab, additionally known as Opdivo Qvantig, will make the therapy faster and simpler for sufferers to get. The injection takes lower than 5 minutes, in contrast with about half-hour for the infusion.
The injection, which is normally given within the stomach or thigh, doesn’t require a surgically implanted port, which is typically wanted for intravenous nivolumab. And the brand new formulation could ultimately permit sufferers to get the therapy at their oncologists’ workplace, and even at residence.
The injectable type of nivolumab permits for better comfort for sufferers whereas sustaining the therapy’s efficacy, mentioned James Gulley, M.D., Ph.D., co-director of NCI’s Heart for Immuno-Oncology.
This isn’t the primary approval of an injectable type of an immune checkpoint inhibitor. A subcutaneous model of atezolizumab (Tecentriq) was authorized in September. Pharmaceutical corporations are additionally creating subcutaneous variations of different immunotherapy medicine, together with pembrolizumab (Keytruda) and blinatumomab (Blincyto).
The approval of subcutaneous nivolumab is predicated on outcomes from a scientific trial evaluating each types of nivolumab in folks with superior kidney most cancers. The trial confirmed that each types of the drug had comparable pharmacokinetics, which means how the drug is absorbed, damaged down, and excreted within the physique. And subcutaneous nivolumab was as secure and efficient, when it comes to goal response charges, as intravenous nivolumab.
The scientific trial outcomes that shaped the idea for the brand new approval are lined in additional element in this March 2024 Most cancers Currents story.
